Vaccines and the induction of functional antibodies: Time to look beyond the molecules of natural infection? (original) (raw)
References
Hilleman, M.R. Six decades of vaccine development—a personal history. Nature Med.4, 507—514 ( 1998). ArticleCAS Google Scholar
Edelson, B.T., Cossart, P. & Unanue, E.R. Paradigm revisited: antibody provides resistance to Listeria infection. J. Immunol.163, 4087 –4090 (1999). CAS Google Scholar
Casadevall, A. Antibody-mediated protection against intracellular pathogens. Trends Microbiol.6, 102–107 (1998). ArticleCAS Google Scholar
Kostrikis, L.G., Cao, Y., Ngai, H., Moore, J.P. & Ho, D.D. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J. Virol.70, 445–458 ( 1996). CAS Google Scholar
Moore, J.P. et al. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J. Virol.70, 427–444 ( 1996). CAS Google Scholar
Moog, C., Fleury, H.J.A., Pellegrin, I., Kirn, A. & Aubertin, A.M. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J. Virol.71, 3734–3741 (1997). CAS Google Scholar
Gauduin, M.-C. et al. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nature Med.3, 1389–1393 (1997). ArticleCAS Google Scholar
Mascola, J.R. et al. Protection of macaques against pathogenic SHIV-89.6PD by passive transfer of neutralizing antibodies. J. Virol.73, 4009–4018 (1999). CAS Google Scholar
Baba, T.W. et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian/human immunodeficiency virus infection. Nature Med. 6, 200–206 ( 2000). ArticleCAS Google Scholar
Mascola, J.R. et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nature Med. 6, 207–210 ( 2000). ArticleCAS Google Scholar
Sanchez, A. et al. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J. Virol.72, 6442– 6447 (1998). CAS Google Scholar
Maruyama, T. et al. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J. Virol73, 6024–6030 (1999). CAS Google Scholar
Connolly, B.M. et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J. Infect. Dis. 179, (supplement 1 ), 5201–5217 (1999). Google Scholar
Roben, P. et al. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol.68, 4821–4828 (1994). CAS Google Scholar
Sattentau, Q.J. & Moore, J.P. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med.182, 185– 196 (1995). ArticleCAS Google Scholar
Fouts, T.R., Binley, J.M., Trkola, A., Robinson, J.E. & Moore, J.P. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex . J. Virol.71, 2779–2785 (1997). CAS Google Scholar
Parren, P.W.H.I. et al. Neutralization of HIV-1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity . J. Virol.72, 3512–3519 (1998). CAS Google Scholar
Wrin, T. et al. Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.7, 211–219 (1994). CAS Google Scholar
Nyambi, P.N. et al. Study of the dynamics of neutralization escape mutants in a chimpanzee naturally infected with the simian immunodeficiency virus SIV cpz-ant . J. Virol.71, 2320– 2330 (1997). CAS Google Scholar
Murphy, B.R. & Webster, R. in Fields Virology (eds. Fields, B.N., Knipe, D.M. & Howley, P.M.) 1397–1446 (Lippincott-Raven, Philadelphia, Pennsylvania, 1996). Google Scholar
Kwong, P.D. et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature393, 648–659 ( 1998). ArticleCAS Google Scholar
Wyatt, R. et al. The antigenic structure of the HIV gp120 envelope glycoprotein . Nature393, 705–711 (1998). ArticleCAS Google Scholar
Wyatt, R. & Sodroski, J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science280, 1884–1888 (1998). ArticleCAS Google Scholar
Griffin, D. E. & Bellini, W. J. in Fields Virology (eds. Fields, B.N., Knipe, D.M. & Howley, P.M.) 1267– 1312 (Lippincott-Raven, Philadelphia, Pennsylvania, 1996). Google Scholar
Wolinsky, J.S. in Fields Virology (eds. Fields, B.N., Knipe, D.M. & Howley, P.M.) 899–930 (Lippincott-Raven, Philadelphia, Pennsylvania, 1996). Google Scholar
Binley, J.M. et al. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol.74, 627– 643 (2000).
Reitter, J.N., Means, R.E. & Desrosiers, R.C. A role for carbohydrates in immune evasion in AIDS . Nature Med.4, 679–684 (1998). ArticleCAS Google Scholar
Patten, P.A., Howard, R.J. & Stemmer, W.P. Applications of DNA shuffling to pharmaceuticals and vaccines. Curr. Opin. Biotechnol.8, 724 –733 (1997). ArticleCAS Google Scholar
Dempsey, P.W., Allison, M.E.D., Akkaraju, S., Goodnow, C.C. & Fearon, D.T. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science271, 348–350 (1996). ArticleCAS Google Scholar
Barber, B.H. The immunotargeting approach to adjuvant-independent subunit vaccine design . Sem. Immunol.9, 293– 301 (1997). ArticleCAS Google Scholar
Wang, H., Griffiths, M.N., Burton, D.R. & Ghazal, P. Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization. Proc. Natl. Acad. Sci. USA (in the press).
Steward, M.W., Stanley, C.M. & Obeid, O.E. A mimotope from a solid-phase peptide library induces a measles virus-neutralizing and protective antibody response. J. Virol.69, 7668–7673 (1995). CAS Google Scholar
Chargelegue, D. et al. A peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo. J. Virol.72, 2040–2046 (1998). CAS Google Scholar
Puntoriero, G. et al. Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants. EMBO J.17, 3521–3533 (1998). ArticleCAS Google Scholar
Mulligan, M.J. & Weber, J. Human trials of HIV-1 vaccines. AIDS13, S105– S112 (1999). CAS Google Scholar